Platelet Activation Pathways Controlling Reversible Integrin αIIbβ3 Activation
TH Open · 2024-04 · 08 (02) · e232-e242
DOI: 10.1055/s-0044-1786987 ↗Kurz gefasst
Fachartikel in der Zeitschrift TH Open, online erschienen am 22.06.2024. Verfasst von Jinmi Zou und 8 weiteren Autor:innen. Beteiligte Einrichtung: Platelet (patho)physiology, Synapse Research Institute, Maastricht, The Netherlands. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Agonist-induced platelet activation, with the integrin αIIbβ3 conformational change, is required for fibrinogen binding. This is considered reversible under specific conditions, allowing a second phase of platelet aggregation. The signaling pathways that differentiate between a permanent or transient activation state of platelets are poorly elucidated.
Objective
To explore platelet signaling mechanisms induced by the collagen receptor glycoprotein VI (GPVI) or by protease-activated receptors (PAR) for thrombin that regulate time-dependent αIIbβ3 activation.
Methods
Platelets were activated with collagen-related peptide (CRP, stimulating GPVI), thrombin receptor-activating peptides, or thrombin (stimulating PAR1 and/or 4). Integrin αIIbβ3 activation and P-selectin expression was assessed by two-color flow cytometry. Signaling pathway inhibitors were applied before or after agonist addition. Reversibility of platelet spreading was studied by microscopy.
Results
Platelet pretreatment with pharmacological inhibitors decreased GPVI- and PAR-induced integrin αIIbβ3 activation and P-selectin expression in the target order of protein kinase C (PKC) > glycogen synthase kinase 3 > β-arrestin > phosphatidylinositol-3-kinase. Posttreatment revealed secondary αIIbβ3 inactivation (not P-selectin expression), in the same order, but this reversibility was confined to CRP and PAR1 agonist. Combined inhibition of conventional and novel PKC isoforms was most effective for integrin closure. Pre- and posttreatment with ticagrelor, blocking the P2Y12 adenosine diphosphate (ADP) receptor, enhanced αIIbβ3 inactivation. Spreading assays showed that PKC or P2Y12 inhibition provoked a partial conversion from filopodia to a more discoid platelet shape.
Conclusion
PKC and autocrine ADP signaling contribute to persistent integrin αIIbβ3 activation in the order of PAR1/GPVI > PAR4 stimulation and hence to stabilized platelet aggregation. These findings are relevant for optimization of effective antiplatelet treatment.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Platelet (patho)physiology, Synapse Research Institute, Maastricht, The Netherlands.
- Department of Biochemistry and Internal Medicine, Maastricht University Medical Center + , Maastricht, The Netherlands.
ORCID-Profile: Hugo Ten Cate, Frauke Swieringa
Zitieren
APA
Zou, J., Sun, S., De Simone, I., Ten Cate, H., de Groot, P. G., de Laat, B., Roest, M., Heemskerk, J. W. M., & Swieringa, F. (2024). Platelet Activation Pathways Controlling Reversible Integrin αIIbβ3 Activation. TH Open, 08(02), e232-e242. https://doi.org/10.1055/s-0044-1786987
Vancouver
Zou J, Sun S, De Simone I, Ten Cate H, de Groot PG, de Laat B, et al. Platelet Activation Pathways Controlling Reversible Integrin αIIbβ3 Activation. TH Open. 2024;08(02):e232-e242. doi:10.1055/s-0044-1786987
BibTeX
@article{Zou2024,
author = {Zou, Jinmi and Sun, Siyu and De Simone, Ilaria and Ten Cate, Hugo and de Groot, Philip G and de Laat, Bas and Roest, Mark and Heemskerk, Johan W M and Swieringa, Frauke},
title = {Platelet Activation Pathways Controlling Reversible Integrin αIIbβ3 Activation},
journal = {TH Open},
year = {2024},
volume = {08},
number = {02},
pages = {e232--e242},
doi = {10.1055/s-0044-1786987}
}
EUVIMED